Related Experiment Video
Updated: Feb 10, 2026

Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats
Published on: August 1, 2018
Glucocorticoid-dependent hypertension
Insights
Glucocorticoid excess causes hypertension in most Cushing's syndrome patients and 20% of those on GC treatment. This GC-induced hypertension, linked to cardiovascular risks, can be treated with GC antagonists.
Area of Science:
- Endocrinology
- Cardiovascular Medicine
- Pharmacology
Background:
- Glucocorticoid (GC) excess, seen in Cushing's syndrome, is strongly linked to hypertension, affecting over 70% of patients.
- Cardiovascular damage is prevalent in GC-induced hypertension and can occur even in normotensive individuals.
- Excess mortality in Cushing's syndrome is largely attributed to cardiovascular disease, highlighting the systemic impact of GC excess.
Purpose of the Study:
- To investigate the association between glucocorticoid excess and hypertension.
- To explore the mechanisms underlying GC-induced hypertension and its cardiovascular consequences.
- To assess the efficacy of GC antagonists in managing GC-related hypertension.
Main Methods:
- Analysis of hypertension prevalence in Cushing's syndrome patients (n=130).
- Examination of cardiovascular damage in hypertensive and normotensive GC-affected individuals.
- Experimental induction of hypertension using oral cortisol and assessment of vascular responsiveness.
Main Results:
- Hypertension is prevalent in Cushing's syndrome (89/130 patients) and in 20% of patients on oral GC therapy, independent of disease subtype or duration.
- GC-induced hypertension is unresponsive to spironolactone but sensitive to GC antagonists like RU486.
- Experimentally, cortisol administration increased cardiac output and forearm vascular responsiveness, suggesting local vascular mechanisms contribute to hypertension.
Conclusions:
- Glucocorticoid excess is a significant cause of hypertension with substantial cardiovascular implications.
- The hypertension associated with GC excess appears to involve altered vascular responsiveness, potentially mediated by local mechanisms.
- Glucocorticoid antagonists represent a potential therapeutic strategy for managing GC-induced hypertension.
Abstract:
Glucocorticoid (GC) excess (Cushing's syndrome) is associated with hypertension in at least 70% of patients (in our series 89/130), independently of the subtype (pituitary or adrenal) and the duration, but not of the age of the patients. Cardiovascular damage is quite frequent in hypertensives, but is sometimes also present in normotensives. The mortality of patients with Cushing's syndrome is four times that of the general population when matched for age and sex, and much of this excess mortality is caused by cardiovascular disease. Hypertension remits in most of the patients after successful treatment, but may persist in some. Hypertension also occurs in 20% of patients treated with GC orally. The type of hypertension is independent of salt uptake, can not be controlled by spironolactone but is inhibited by a GC antagonist such as RU486. Experimentally-induced hypertension with oral cortisol (F) is associated with a rise in cardiac output, a fall in calculated total peripheral resistance, an increased forearm vascular responsiveness to exogenous norepinephrine, but no change in overall sympathetic tone, or in norepinephrine reuptake. The increased pressor responsiveness is probably due to local postsynaptic effector mechanisms in the resistance vessels, which could be important in phasic increases in neuronally mediated constrictor responses. Both in patients with Cushing's syndrome and in those on chronic GC treatment, the circadian blood pressure variations are absent or reversed. This may contribute to the deleterious effects of the GC excess on blood vessels. The vascular effects of the GC may be mediated by the activation of specific cardiovascular receptors, by modulating vascular transport systems, or by altered catecholamine or prostaglandin metabolism. GC may also act as mineralocorticoids (MC): in fact type 1 MC receptors are unable, in vitro, to distinguish between aldosterone and cortisol. The specificity-conferring mechanism of typical target organs for MC (e.g. kidney)--is thought to be due to the action of local 11-beta-hydroxysteroid dehydrogenase, which converts F to biologically inactive cortisone (E). When the activity of the enzyme is impaired (syndrome of apparent MC excess, liquorice or carbenoxolone administration), F acts as a MC and MC-hypertension with hypokalemia occurs.(ABSTRACT TRUNCATED AT 400 WORDS)
Related Concept Videos
Hypertension II: Pathophysiology
Hypertension I: Introduction
Hypertension V: Nursing Management
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Frequency-dependent Selection

